Pomalyst.com
Treating Patients with Multiple Myeloma | POMALYST® (pomalidomide)
Domain Summary
What is the traffic rank for Pomalyst.com?
• Pomalyst.com ranks #1,852,968 globally on HypeStat.
What percent of global Internet users visit Pomalyst.com?
• 2.1E-5% of global Internet users visit Pomalyst.com
How many people visit Pomalyst.com each day?
• Pomalyst.com receives approximately 1K visitors and 4,245 page impressions per day.
Which countries does Pomalyst.com receive most of its visitors from?
• Pomalyst.com is mostly visited by people located in United States.
How much Pomalyst.com can earn?
• Pomalyst.com should earn about $20.50/day from advertising revenue.
What is Pomalyst.com estimated value?
• Estimated value of Pomalyst.com is $18,682.89.
What IP addresses does Pomalyst.com resolve to?
• Pomalyst.com resolves to the IP addresses 52.204.5.37.
Where are Pomalyst.com servers located in?
• Pomalyst.com has servers located in Wilmington, DE, 19893, United States.
pomalyst.com Profile
Title:Treating Patients with Multiple Myeloma | POMALYST® (pomalidomide)
Description:Learn more about treatment options available for Multiple Myeloma, including efficacy, dosing, safety information and more Important Safety Information WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal ***. In females of reproductive potential, obtain 2 negative pregnancy tests before starting POMALYST treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual *** during and for 4 weeks after stopping POMALYST treatment. POMALYST is only available through a restricted distribution program called POMALYST REMS®. Venous and Arterial Thromboembolism Deep venous thrombosis (DVT), pulmonary *** (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Prophylactic antithrombotic measures were employed in clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient’s underlying risk factors. CONTRAINDICATIONS: Pregnancy POMALYST can cause fetal harm and is contraindicated in females who are pregnant. If POMALYST is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus WARNINGS AND PRECAUTIONS Embryo-Fetal Toxicity Females of Reproductive Potential: Must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy. Must commit either to abstain continuously from heterosexual *** intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. Must obtain 2 negative pregnancy tests prior to initiating therapy Males: Pomalidomide is present in the *** of patients receiving the drug. Males must always use a *** or synthetic *** during any *** contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy. Males must not donate sperm Blood Donation: Patients must not donate blood during treatment with POMALYST and for 1 month following discontinuation of POMALYST therapy because the blood might be given to a pregnant female patient whose fetus must not be exposed to POMALYST POMALYST REMS® Program Because of the embryo-fetal risk, POMALYST is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called “POMALYST REMS®.” Prescribers and pharmacies must be certified with the program; patients must sign an agreement form and comply with the requirements. Further information about the POMALYST REMS® program is available at www.CelgeneRiskManagement.com or by telephone at 1-888-423-5436. Venous and Arterial Thromboembolism: Venous thromboembolic events (DVT and PE) and arterial thromboembolic events (ATE) (myocardial infarction and stroke) have been observed in patients treated with POMALYST. In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low-dose dexamethasone (Low-dose Dex) vs 3.3% treated with high-dose dexamethasone. Venous thromboembolic events (VTE) occurred in 4.7% of patients treated with POMALYST and Low-dose Dex vs 1.3% treated with high-dose dexamethasone. Arterial thromboembolic events include terms for arterial thromboembolic events, ischemic cerebrovascular conditions, and ischemic heart disease. Arterial thromboembolic events occurred in 3.0% of patients treated with POMALYST and Low-dose Dex vs 1.3% treated with high-dose dexamethasone. Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Hematologic Toxicity: In Trials 1 and 2 in patients who received POMALYST + Low-dose Dex, neutropenia (46%) was the most frequently reported Grade 3/4 adverse reaction, followed by anemia and thrombocytopenia. Monitor patients for hematologic toxicities, especially neutropenia. Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter. Patients may require dose interruption and/or modification. Hepatotoxicity: Hepatic failure, including fatal cases, has occurred in patients treated with POMALYST. Elevated levels of alanine aminotransferase and bilirubin have also been observed in patients treated with POMALYST. Monitor liver function tests monthly. Stop POMALYST upon elevation of liver enzymes. After return to baseline values, treatment at a lower dose may be considered. Hypersensitivity Reactions: Angioedema and severe dermatologic reactions have been reported. Discontinue POMALYST for angioedema, skin exfoliation, bullae, or any other severe dermatologic reactions, and do not resume therapy. Dizziness and Confusional State: In Trials 1 and 2 in patients who received POMALYST + Low-dose Dex, 14% experienced dizziness and 7% a confusional state; 1% of patients experienced Grade 3 or 4 dizziness and 3% experienced a Grade 3 or 4 confusional state. Instruct patients to avoid situations where dizziness or confusional state may be a problem and not to take other medications that may cause dizziness or confusional state without adequate medical advice. Neuropathy: In Trials 1 and 2, patients who received POMALYST + Low-dose Dex experienced neuropathy (18%) and peripheral neuropathy (~12%). In Trial 2, 2% of patients experienced Grade 3 neuropathy. Risk of Second Primary Malignancies: Cases of acute myelogenous leukemia have been reported in patients receiving POMALYST as an investigational therapy outside of multiple myeloma. Tumor Lysis Syndrome: Tumor lysis syndrome (TLS) may occur in patients treated with POMALYST. Patients at risk are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken. ADVERSE REACTIONS Nearly all patients treated with POMALYST + Low-dose Dex experienced at least one adverse reaction (99%). In Trial 2, the most common adverse reactions included neutropenia (51.3%), fatigue and asthenia (46.7%), upper respiratory tract infection (31%), thrombocytopenia (29.7%), pyrexia (26.7%), dyspnea (25.3%), diarrhea (22%), constipation (21.7%), back pain (19.7%), cough (20%), pneumonia (19.3%), edema peripheral (17.3%), peripheral neuropathy (17.3%), bone pain (18%), nausea (15%), and muscle spasms (15.3%). Grade 3 or 4 adverse reactions included neutropenia (48.3%), thrombocytopenia (22%), and pneumonia (15.7%). DRUG INTERACTIONS Pomalidomide is primarily metabolized by CYP1A2 and CYP3A. Pomalidomide is also a substrate for P-glycoprotein (P-gp). Avoid the use of strong CYP1A2 inhibitors. If medically necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, reduce POMALYST dose by 50%. Cigarette smoking may reduce pomalidomide exposure due to CYP1A2 induction. Patients should be advised that smoking may reduce the efficacy of pomalidomide. USE IN SPECIFIC POPULATIONS Pregnancy: If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Report any suspected fetal exposure to POMALYST to the FDA via the MedWatch program at 1-800-332-1088 and also to Celgene Corporation at 1-888-423-5436. Nursing Mothers: It is not known if pomalidomide is excreted in human milk. Pomalidomide was excreted in the milk of lactating rats. Because many *** are excreted in human milk and because of the potential for adverse reactions in nursing infants from POMALYST, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the moth
What technologies does pomalyst.com use?
These are the technologies used at pomalyst.com. pomalyst.com has a total of 9 technologies installed in 10 different categories.pomalyst.com Traffic Analysis
Pomalyst.com is ranked #1,852,968 in the world. This website is viewed by an estimated 1K visitors daily, generating a total of 4.2K pageviews. This equates to about 31.4K monthly visitors.Daily Visitors1K
Monthly Visits31.4K
Pages per Visit4.10
Visit duration n/a
Bounce Rate n/a
Is this your site?Verify your site's metrics.
- Daily Unique Visitors:
- 1,035
- Monthly Visits:
- 31,361
- Pages per Visit:
- 4.10
- Daily Pageviews:
- 4,245
- Avg. visit duration:
- n/a
- Bounce rate:
- n/a
- Global Reach:
- 2.1E-5%
- HypeRank:
- 1,852,968
- SEMrush Rank:
- 547,679
Visitors by country
- Country
- Users%
- United States 100.0%
Where do visitors go on pomalyst.com?
- Reach%Pageviews%PerUser
- pomalyst.com
- 100.00%100.00%2.6
Backlinks Report ▼
Pomalyst.com has a total of 70 backlinks from 22 referring domains.- Total Backlinks:
- 70
- Follow Links:
- 69
- Nofollow Links:
- 1
- Referring Domains:
- 22
- Referring IPs:
- 21
- Authority Domain Score:
- 0
Last update was 1982 days ago
This can take up to 60 seconds. Please wait...
This can take up to 60 seconds. Please wait...
*HypeStat.com is not promoting or affiliated with pomalyst.com in any way. Only publicly available statistics data are displayed.
▼
SEMrush is a complete on line advertising and marketing platform that gives a extensive variety of gear and functions to help companies and entrepreneurs in enhancing their on line visibility and optimizing their virtual advertising and marketing strategies.- Domain:
- pomalyst.com
- Rank:
(Rank based on keywords, cost and organic traffic) - 547,679
- Organic Keywords:
(Number of keywords in top 20 Google SERP) - 297
- Organic Traffic:
(Number of visitors coming from top 20 search results) - 908
- Organic Cost:
((How much need to spend if get same number of visitors from Google Adwords) - $10,594.00
Revenue report ▼
Google.com would generate approximately $20.5 per day if the source of income were advertisements, which equates to an estimated monthly revenue of $615 and annual gross revenue of approximately $7.5K. Based on these figures, the site's net worth is estimated at around $18.7K.How much would pomalyst.com make?
- Daily Revenue:
- $20.50
- Monthly Revenue:
- $615.00
- Yearly Revenue:
- $7,482.50
Daily earning by country
- CountryPageviewsEarning
- United States 4,245$20.50
Loss of money due to Adblock?
- Daily Revenue Loss:
- $3.69
- Monthly Revenue Loss:
- $110.72
- Yearly Revenue Loss:
- $1,347.07
- Daily Pageviews Blocked:
- 764
- Monthly Pageviews Blocked:
- 22,923
- Yearly Pageviews Blocked:
- 278,897
Daily revenue loss by country
- CountryBlockedLost Money
- United States 764$3.69
How much is pomalyst.com worth?
- Website Value:
- $18.7K
Ad Experience Report ▼
Summary of the ad experience rating of a website for a specific platform.Mobile summary
- Root domain:
- pomalyst.com
- Ad filtering:
(Chrome is not filtering ads on your site.) - Off
- Status:
(The status of the site that is reviewed for the Better Ads Standards.) - Not reviewed
Desktop summary
- Root domain:
- pomalyst.com
- Ad filtering:
(Chrome is not filtering ads on your site.) - Off
- Status:
(The status of the site that is reviewed for the Better Ads Standards.) - Not reviewed
Abusive Experience Report ▼
Summary of the abusive experience rating of a website.- Root domain:
- pomalyst.com
- Enforcement:
(Chrome is not preventing your site from opening new windows or tabs.) - Off
- Status:
(The status of the site reviewed for the abusive experiences.) - Not reviewed
Where is pomalyst.com hosted? ▼
Pomalyst.com may be hosted in multiple data centers distributed in different locations around the world. This is probably just one of them.- Server IP:
- 52.204.5.37
- ASN:
- AS8001
- ISP:
- Net Access Corporation
- Server Location:
- Wilmington
DE
19893
United States
Other sites hosted on 52.204.5.37
There are no other sites hosted on this IPHow fast does pomalyst.com load? ▼
The average loading time of pomalyst.com is n/a ms. The Desktop speed index is 48 and mobile speed index is 61.- Average Load Time:
- n/a ms
Page Speed (Google PageSpeed Insights) - Desktop
Field Data
Over the last 30 days, the field data shows that this page has a speed compared to other pages in the Chrome User Experience Report.We are showing the 90th percentile of FCP and the 95th percentile of FID.
Cumulative Layout Shift (CLS)0
Time To First Byte (TTFB)0
First Contentful Paint (FCP)0
First Input Delay (FID)0
Interaction To Next Paint (INP)0
Largest Contentful Paint (LCP)0
Origin Data
All pages served from this origin have an speed compared to other pages in the Chrome User Experience Report. over the last 30 days.To view suggestions tailored to each page, analyze individual page URLs.
Cumulative Layout Shift (CLS)0
Time To First Byte (TTFB)0
First Contentful Paint (FCP)0
First Input Delay (FID)0
Interaction To Next Paint (INP)0
Largest Contentful Paint (LCP)0
Lab Data
Page Speed (Google PageSpeed Insights) - Mobile
Field Data
Over the last 30 days, the field data shows that this page has a speed compared to other pages in the Chrome User Experience Report.We are showing the 90th percentile of FCP and the 95th percentile of FID.
Cumulative Layout Shift (CLS)0
Time To First Byte (TTFB)0
First Contentful Paint (FCP)0
First Input Delay (FID)0
Interactive To Next Paint (INP)0
Largest Contentful Paint (LCP)0
Origin Data
All pages served from this origin have an speed compared to other pages in the Chrome User Experience Report. over the last 30 days.To view suggestions tailored to each page, analyze individual page URLs.
Cumulative Layout Shift (CLS)0
Time To First Byte (TTFB)0
First Contentful Paint (FCP)0
First Input Delay (FID)0
Interactive To Next Paint (INP)0
Largest Contentful Paint (LCP)0
Lab Data
Does pomalyst.com use compression? ▼
Website compression is the process of reducing the size of website files, such as HTML, CSS, JavaScript, and image files, to improve website performance and load times. Compressing website files can significantly reduce the amount of data that needs to be transferred from the server to the user's browser, resulting in faster page load times and improved user experience. Files on pomalyst.com are reduced by %.
pomalyst.com does not use compression.
Original size: n/a
Compressed size: n/a
File reduced by: (%)
Compressed size: n/a
File reduced by: (%)
Google Safe Browsing ▼
Google Safe Browsing is a service provided by Google that helps protect users from visiting websites that may contain malicious or harmful content, such as malware, phishing attempts, or deceptive software.SSL Checker - SSL Certificate Verify ▼
An SSL (Secure Sockets Layer) certificate is a digital certificate that establishes a secure encrypted connection between a web server and a user's web browser. It provides authentication and encryption, ensuring that data transmitted between the server and the browser remains private and protected. pomalyst.com does not support HTTPS. pomalyst.com does not support HTTPS
Verifying SSL Support. Please wait...
Verify HTTP/2 Support ▼
HTTP/2 (Hypertext Transfer Protocol version 2) is a major revision of the HTTP protocol, which is the foundation of data communication on the World Wide Web. It was developed as an improvement over the previous HTTP/1.1 version to enhance web performance and efficiency. pomalyst.com does not support HTTP/2
Verifying HTTP/2.0 Support. Please wait...
Http Header ▼
HTTP headers are extra portions of records despatched among a consumer (which include an internet browser) and a server at some stage in an HTTP request or response. They offer instructions, metadata, or manipulate parameters for the conversation among the consumer and server.HTTP/1.1 200 OK
Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0
Content-Type: text/html; charset=UTF-8
Date: Tue, 23 Feb 2016 17:51:57 GMT
Expires: Thu, 19 Nov 1981 08:52:00 GMT
Link: <http://www.pomalyst.com/>; rel=shortlink
Pragma: no-cache
Server: Apache
Set-Cookie: PHPSESSID=nrgbsqdo5da9gep9baub1dcnj0; path=/
Set-Cookie: AWSELB=CFF1DB390C36F045AA6C066CFCC86E65946379AA4B31D6C83A9F7E30A91D7536C078D50C893B44D3A1D14256FAF5CFAD4ED3327594FD8FD3CFB13D43842A44E6FA8889FBBBBD3190D54185A3E4021B21678084B5A2;PATH=/
X-Frame-Options: SAMEORIGIN
X-Pingback: http://www.pomalyst.com/xmlrpc.php
X-Powered-By: PHP/5.6.16
X-XSS-Protection: 1; mode=block
Connection: Close
Whois Lookup ▼
Domain WHOIS is a public database that provides information about domain names, including registered owners, contact information, domain registrars, registration and expiration dates, name servers, and other relevant information. Domain registration for this website began on September 24, 2012 and will expire on January 17, 2026 if not renewed. This website is now assigned through the registrar . The WHOIS data for this website's domain was last updated on January 17, 2026.- Domain Created:
- 2012-09-24
- Domain Age:
- 13 years 3 months 23 days
- WhoIs:
whois lookup at whois.corporatedomains.com...Domain Name: pomalyst.com Registry Domain ID: 1747282810_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: www.cscprotectsbrands.com Updated Date: 2015-09-21T06:31:46Z Creation Date: 2012-09-24T09:15:28Z Registrar Registration Expiration Date: 2016-09-24T09:15:28Z Registrar: CSC CORPORATE DOMAINS, INC. Sponsoring Registrar IANA ID: 299 Registrar Abuse Contact Email:Registrar Abuse Contact Phone: +1.8887802723 Domain Status: clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited Registry Registrant ID: Registrant Name: Domain Administrator Registrant Organization: Celgene Corporation Registrant Street: 86 Morris Avenue Registrant City: Summit Registrant State/Province: NJ Registrant Postal Code: 07901 Registrant Country: US Registrant Phone: +1.9086739000 Registrant Phone Ext: Registrant Fax: +1.9086739001 Registrant Fax Ext: Registrant Email:
Registry Admin ID: Admin Name: Domain Administrator Admin Organization: Celgene Corporation Admin Street: 86 Morris Avenue Admin City: Summit Admin State/Province: NJ Admin Postal Code: 07901 Admin Country: US Admin Phone: +1.9086739000 Admin Phone Ext: Admin Fax: +1.9086739001 Admin Fax Ext: Admin Email:
Registry Tech ID: Tech Name: DNS Administrator Tech Organization: CSC Corporate Domains, Inc. Tech Street: 2711 Centerville Road Tech City: Wilmington Tech State/Province: DE Tech Postal Code: 19808 Tech Country: US Tech Phone: +1.3026365400 Tech Phone Ext: Tech Fax: +1.3026365454 Tech Fax Ext: Tech Email:
Name Server: dns1.cscdns.net Name Server: dns2.cscdns.net DNSSEC: unsigned URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/ >>> Last update of WHOIS database: 2015-09-21T06:31:46Z <<< Corporation Service Company(c) (CSC) The Trusted Partner of More than 50% of the 100 Best Global Brands. Contact us to learn more about our enterprise solutions for Global Domain Name Registration and Management, Trademark Research and Watching, Brand, Logo and Auction Monitoring, as well SSL Certificate Services and DNS Hosting. NOTICE: You are not authorized to access or query our WHOIS database through the use of high-volume, automated, electronic processes or for the purpose or purposes of using the data in any manner that violates these terms of use. The Data in the CSC WHOIS database is provided by CSC for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. CSC does not guarantee its accuracy. By submitting a WHOIS query, you agree to abide by the following terms of use: you agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via direct mail, e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to CSC (or its computer systems). CSC reserves the right to terminate your access to the WHOIS database in its sole discretion for any violations by you of these terms of use. CSC reserves the right to modify these terms at any time. Register your domain name at http://www.cscglobal.com For more information on Whois status codes, please visit https://www.icann.org/resources/pages/epp-status-codes-2014-06-16-enwhois lookup at whois.crsnic.net...Whois Server Version 2.0 Domain names in the .com and .net domains can now be registered with many different competing registrars. Go to http://www.internic.net for detailed information. Domain Name: POMALYST.COM Registrar: CSC CORPORATE DOMAINS, INC. Sponsoring Registrar IANA ID: 299 Whois Server: whois.corporatedomains.com Referral URL: http://www.cscglobal.com/global/web/csc/digital-brand-services.html Name Server: DNS1.CSCDNS.NET Name Server: DNS2.CSCDNS.NET Status: clientTransferProhibited https://www.icann.org/epp#clientTransferProhibited Updated Date: 21-sep-2015 Creation Date: 24-sep-2012 Expiration Date: 24-sep-2016 >>> Last update of whois database: Tue, 23 Feb 2016 17:51:34 GMT <<< For more information on Whois status codes, please visit https://icann.org/epp NOTICE: The expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. This date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. Users may consult the sponsoring registrar's Whois database to view the registrar's reported date of expiration for this registration. TERMS OF USE: You are not authorized to access or query our Whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary to register domain names or modify existing registrations; the Data in VeriSign Global Registry Services' ("VeriSign") Whois database is provided by VeriSign for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. VeriSign does not guarantee its accuracy. By submitting a Whois query, you agree to abide by the following terms of use: You agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to VeriSign (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of VeriSign. You agree not to use electronic processes that are automated and high-volume to access or query the Whois database except as reasonably necessary to register domain names or modify existing registrations. VeriSign reserves the right to restrict your access to the Whois database in its sole discretion to ensure operational stability. VeriSign may restrict or terminate your access to the Whois database for failure to abide by these terms of use. VeriSign reserves the right to modify these terms at any time. The Registry database contains ONLY .COM, .NET, .EDU domains and Registrars.